What is Zymeworks's AFS securities?

Zymeworks (ZYME) reported AFS securities of $159.47M in Q1 2026.

How has Zymeworks's AFS securities changed year-over-year?

Zymeworks's AFS securities decreased by 35.0% year-over-year, from $245.15M to $159.47M.

What is the long-term trend for Zymeworks's AFS securities?

Over 2 years (2023 to 2025), Zymeworks's AFS securities has grown at a -12.5% compound annual growth rate (CAGR), from $298.64M to $228.84M.

What does AFS securities mean?

Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.

Zymeworks ZYME AFS Securities

AFS Securities at other companies

Stoke Therapeutics, Inc.STOK

$67.48M+194%

Ligand PharmaceuticalsLGND

$237M+4,934%

Adaptive BiotechnologiesADPT

$18.89M-52.0%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Enterprise value$1.56B+112%

P/S22×+13.5×

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's AFS securities?: Zymeworks (ZYME) reported AFS securities of $159.47M in Q1 2026.
How has Zymeworks's AFS securities changed year-over-year?: Zymeworks's AFS securities decreased by 35.0% year-over-year, from $245.15M to $159.47M.
What is the long-term trend for Zymeworks's AFS securities?: Over 2 years (2023 to 2025), Zymeworks's AFS securities has grown at a -12.5% compound annual growth rate (CAGR), from $298.64M to $228.84M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.